Literature DB >> 22410053

Primary versus salvage living donor liver transplantation for patients with hepatocellular carcinoma: impact of microvascular invasion on survival.

J I Moon1, C H D Kwon, J W Joh, G S Choi, G O Jung, J M Kim, M Shin, S J Choi, S J Kim, S-K Lee.   

Abstract

OBJECTIVE: Salvage liver transplantation (LT) has been proposed for patients with a small hepatocellular carcinoma (HCC) and preserved liver function. Few reports have been issued on salvage LT in a living-donor (LD) LT setting. Therefore, we performed this study to evaluate differences in tumor invasiveness and other risk factors on survival after salvage versus primary LDLT.
METHODS: Between September 1996 and December 2008, 324 patients with HCC underwent LT. We excluded 138 patient from the analysis, leaving 186 HCC patients for analysis, including 17 (9.1%) who had undergone earlier resection, the salvage LDLT cohort. The other 169 patients underwent primary LDLT.
RESULTS: Intrahepatic metastasis, Edmonson-Steiner histologic grade, microscopic vascular invasion, and preoperative serum alpha-fetoprotein levels significantly influenced tumor recurrence. Microscopic vascular invasion, intrahepatic metastasis, Edmonson-Steiner histologic grade, and treatment by salvage LDLT were significantly associated with poor patient survival univariate analysis. However, only microscopic vascular invasion was significant on multivariate analysis. The treatment modality (primary or salvage LDLT) was not observed to affect overall or disease-free survival significantly on multivariate analysis. Disease-free survival was significantly better in the primary than in the salvage LDLT group. Furthermore, patients in the primary LDLT group tended to show better survival. However, when stratified by the presence or absence of microscopic vascular invasion, no significant group difference was found for overall or disease-free survival among those without versus with microscopic vascular invasion.
CONCLUSIONS: Five-year overall survival after primary versus salvage LDLT were similar when differences in tumor pathologic features, such as microscopic vascular invasion, were taken into account. Multivariate analysis showed that the treatment itself was not a significant prognostic factor for survival. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22410053     DOI: 10.1016/j.transproceed.2011.11.009

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  20 in total

1.  2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma.

Authors: 
Journal:  Korean J Radiol       Date:  2015-05-13       Impact factor: 3.500

Review 2.  Management of "very early" hepatocellular carcinoma on cirrhotic patients.

Authors:  Gonzalo Sapisochin; Elena Fernandez de Sevilla; Juan Echeverri; Ramón Charco
Journal:  World J Hepatol       Date:  2014-11-27

Review 3.  Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation.

Authors:  Maurizio Pompili; Giampiero Francica; Francesca Romana Ponziani; Roberto Iezzi; Alfonso Wolfango Avolio
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

4.  2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Gut Liver       Date:  2015-05-23       Impact factor: 4.519

5.  Impact of pathological features of primary hepatocellular carcinoma on the outcomes of intrahepatic recurrence management: single center experience from Southern Taiwan.

Authors:  Mahmoud Abdelwahab Ali; Wei-Feng Li; Jing-Houng Wang; Chih-Che Lin; Ying-Ju Chen; Ting-Lung Lin; Tsan-Shiun Lin; Sheng-Nan Lu; Chih-Chi Wang; Chao-Long Chen
Journal:  HPB (Oxford)       Date:  2016-08-25       Impact factor: 3.647

Review 6.  Diagnostic and therapeutic management of hepatocellular carcinoma.

Authors:  Francesco Bellissimo; Marilia Rita Pinzone; Bruno Cacopardo; Giuseppe Nunnari
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

Review 7.  Liver transplantation for hepatocellular carcinoma.

Authors:  Jerome Byam; John Renz; J Michael Millis
Journal:  Hepatobiliary Surg Nutr       Date:  2013-02       Impact factor: 7.293

Review 8.  Salvage liver transplant for hepatocellular carcinoma: rescues and benefits.

Authors:  Shusen Zheng; Qinfen Xie; Jinkun Cheng
Journal:  Transl Gastroenterol Hepatol       Date:  2018-09-17

9.  Salvage liver transplantation for recurrent hepatocellular carcinoma within UCSF criteria after liver resection.

Authors:  Fei Liu; Yonggang Wei; Wentao Wang; Kefei Chen; Lvnan Yan; Tianfu Wen; Jichun Zhao; Mingqing Xu; Bo Li
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

10.  Scoring selection criteria including total tumour volume and pretransplant percentage of lymphocytes to predict recurrence of hepatocellular carcinoma after liver transplantation.

Authors:  Chuan Li; Tian-Fu Wen; Lu-Nan Yan; Bo Li; Jia-Ying Yang; Ming-Qing Xu; Wen-Tao Wang; Yong-Gang Wei
Journal:  PLoS One       Date:  2013-08-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.